- Home
- RARE vs SYNA Comparison
RARE vs SYNA Comparison
Compare RARE & SYNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | SYNA |
|---|---|---|
| Founded | 2010 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.9B |
| IPO Year | 2014 | 2002 |
Fundamental Metrics
Financial Performance| Metric | RARE | SYNA |
|---|---|---|
| Price | $34.86 | $74.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 9 |
| Target Price | $85.20 | ★ $89.78 |
| AVG Volume (30 Days) | ★ 1.5M | 525.0K |
| Earning Date | 11-04-2025 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $630,598,000.00 | ★ $1,109,100,000.00 |
| Revenue This Year | $19.09 | $11.70 |
| Revenue Next Year | $20.62 | $11.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 20.63 | 13.24 |
| 52 Week Low | $25.81 | $41.80 |
| 52 Week High | $46.50 | $89.81 |
Technical Indicators
Market Signals| Indicator | RARE | SYNA |
|---|---|---|
| Relative Strength Index (RSI) | 52.17 | 55.89 |
| Support Level | $32.64 | $73.03 |
| Resistance Level | $36.81 | $81.85 |
| Average True Range (ATR) | 1.60 | 2.78 |
| MACD | -0.29 | -0.36 |
| Stochastic Oscillator | 28.83 | 36.28 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About SYNA Synaptics Incorporated $0.001 Par Value
Synaptics Inc is a producer of semiconductor solutions for the mobile, PC, and Internet of Things markets. The company develops human interface solutions that enable touch, display, fingerprint, video, audio, voice, AI, and connectivity functions for smartphones, PCs, Internet of Things products, and other electronic devices. It operates in one segment: the development, marketing, and sale of semiconductor products used in electronic devices and products. The company geographically, it derives a majority of revenue from China, and also has its presence in Taiwan, Japan, South Korea, United States and Other countries.